New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing.
New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary bioinformatics pipeline, Delve Decide. The data will be presented at the Pan American Society for Clinical Virology (PASCV) Annual Meeting on May 8, 2025, in Clearwater, Florida.
Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, will share data about its groundbreaking mNGS test, Delve Detect, at the 2025 American Academy of Neurology Annual Meeting today in San Diego. With the ability to identify more than 68,000 pathogens with a single test, Delve’s mNGS technology delivers greater diagnostic yield over conventional methods of diagnosing meningitis and encephalitis.
Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect
Delve Bio, a pioneer in metagenomic sequencing, today announced the commercial launch of Delve Detect, its groundbreaking metagenomic test for infectious diseases. Built on the platform developed at University of California San Francisco (UCSF), Delve Detect offers genomic testing of cerebrospinal fluid (CSF) for more than 68,000 pathogens, with 48-hour turnaround time and metagenomics experts readily available to discuss results.
Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data from a seven-year study showing mNGS delivered the highest diagnostic yield of any test, identifying more pathogens than all other methods of direct organism detection (culture, antigen testing, PCR) combined. The findings were presented at the Association for Molecular Pathology 2024 Annual Meeting in Vancouver, B.C.
Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced Nature Medicine has published its study demonstrating the clinical utility of mNGS testing to identify difficult-to-detect pathogens among adults and children with serious central nervous system infections. Soon to be widely available through the company’s Delve Detect testing service, the study showed mNGS testing is more sensitive than direct-detection testing.
Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced data from a study highlighting the utility and diagnostic yield of mNGS testing in cases of infectious meningitis, encephalitis, and/or myelitis among both adults and children at the American Society of Microbiology Microbe conference in Atlanta.
